Acrigen Biosciences develops precision gene editing systems utilizing proprietary αCas and μCas CRISPR-Cas nucleases paired with engineered anti-CRISPR proteins to enhance the accuracy and safety of genetic therapies. The company aims to address genetic disorders by providing targeted and efficient gene editing solutions for human therapeutics.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NSFounders
Product
Problem
Current CRISPR-Cas gene editing technologies can suffer from off-target effects, leading to unintended mutations and safety concerns in therapeutic applications. Existing systems may also lack the efficiency needed for effective gene correction in certain cell types or tissues.
Solution
Acrigen Biosciences is developing precision gene editing systems that combine novel CRISPR-Cas nucleases (αCas and μCas) with engineered anti-CRISPR proteins (ErAcrs) to enhance the accuracy and safety of genetic therapies. The αCas and μCas nuclease libraries are fine-tuned for human gene editing, offering improved efficiency and specificity. The ErAcr proteins selectively inhibit the CRISPR-Cas nuclease, eliminating off-target gene editing. This combined approach aims to improve the efficacy and safety of novel gene editing therapies for both _in vivo_ and _ex vivo_ applications.
Target Audience
The primary target audience includes researchers and companies involved in developing gene editing therapies for human genetic disorders.
Features
- αCas and μCas nuclease libraries: Novel CRISPR-Cas enzymes engineered for human gene editing.
- ErAcr proteins: Engineered Recombinant Anti-CRISPR proteins that selectively inhibit CRISPR-Cas nucleases to minimize off-target effects.
- Nuclease Discovery Engine: Platform for identifying and optimizing CRISPR-Cas enzymes.
- Optimized for both _in vivo_ and _ex vivo_ applications.